Safety and Effectiveness of Endoscopic Intestinal Re-Cellularization Therapy in Individuals With Type II Diabetes

A trial with no phase registered on ClinicalTrials.gov. The registry status is active, not recruiting. It enrolled 350 participants.

Also called NCT06267391

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Not applicable
Enrolled
  • 350 participants (enrolled count) (from the registry)
Sponsor
Endogenex, Inc. (from the registry)
Registry
  • NCT NCT06267391
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
United States, Australia (from the registry)
Registry status
  • Active, not recruiting (from the registry)

Technical summary

Registry record NCT06267391. Randomized; quadruple masking; primary purpose treatment. Start 2024-05-01 (actual); primary completion 2027-02-01 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Safety and Effectiveness of Endoscopic Intestinal Re-Cellularization Therapy in Individuals With Type II Diabetes
Condition
Type 2 Diabetes Mellitus
Condition
Type2diabetes
Condition
Diabetes Mellitus, Type 2
Condition
Diabetes
Condition
Type 2 Diabetes
Intervention (Device)
Endogenex Treatment
Intervention (Device)
Sham Procedure
Lead sponsor
Endogenex, Inc. (class: industry)

Record details

Record id
cardio:ct-nct06267391
Content hash
8bf751939be734e013b98be8a8b6a760b5ff053cf5403ceb6ec4510ffbeadc94